Pemafibrate
Pemafibrate, marketed as Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.
 | |
| Clinical data | |
|---|---|
| Trade names | Parmodia |
| Other names | K-13675 |
| Routes of administration | Oral |
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H30N2O6 |
| Molar mass | 490.556 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
In 3 July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan. It is available in 0.1 mg tablets.[1]
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.